RecruitingNCT06841653

A.I and Machine Learning Based Risk Prediction Model to Improve the Clinical Management of Endometrial Cancer.

A.I and Machine Learning Based Risk Prediction Model to Improve the Clinical Management of Endometrial Cancer: a Composite Approach Integrating the MultiOMics IMmune-IConographic Pattern (MOMIMIC Score) Towards Precision Oncology and Surgery.


Sponsor

Regina Elena Cancer Institute

Enrollment

40 participants

Start Date

Jun 20, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

Prediction of preoperative endometrial biopsy: the evolution from hyperplasia to cancer, the prognosis and the risk of recurrence. Intelligence methods artificial risk will be used to redefine the current risk classes including our profile immuno-mutational to provide a more precise characterization and closer to the real prognosis of the patient.


Eligibility

Sex: FEMALEMin Age: 18 Years

Inclusion Criteria3

  • Age \> 18 years;
  • Histological diagnosis of endometrial hyperplasia, endometrioid adenocarcinoma of the endometrium, healthy endometrium in patients undergoing total hysterectomy for benign extra-endometrial disease;
  • Written informed consent (to the study and data processing), for the party's patients only prospective and/or in follow-up) For the retrospective cohort: availability of samples adequately stored at the biobank of the Institute and availability of data relating to follow-up (at least 2 years)

Exclusion Criteria6

  • Comorbidities not controlled with adequate medical therapy;
  • Infections of the endometrial cavity (pyometra);
  • Synchronous cancer;
  • Neoadjuvant treatments;
  • Previous radiotherapy treatments of the pelvic region;
  • Hormone therapies.

Locations(1)

IRCCS National Cancer Institute "Regina Elena"

Rome, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06841653


Related Trials